NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis $1.37 +0.03 (+2.54%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Galectin Therapeutics Stock (NASDAQ:GALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galectin Therapeutics alerts:Sign Up Key Stats Today's Range$1.33▼$1.4050-Day Range$1.22▼$1.7752-Week Range$0.73▼$3.78Volume29,779 shsAverage Volume316,558 shsMarket Capitalization$86.81 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company OverviewGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Read More… Galectin Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreGALT MarketRank™: Galectin Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 825th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingGalectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGalectin Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Galectin Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.09% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 28.4, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently decreased by 3.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.09% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 28.4, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently decreased by 3.19%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.10% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GALT Stock News HeadlinesGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 CongressApril 15, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)April 2, 2025 | markets.businessinsider.comThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free. April 24, 2025 | Crypto 101 Media (Ad)Galectin Therapeutics reports FY24 EPS (76c) vs (74c) last yearApril 2, 2025 | markets.businessinsider.comGalectin Therapeutics Reports 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comWhile insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownershipMarch 8, 2025 | finance.yahoo.comGalectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE TrialFebruary 18, 2025 | markets.businessinsider.comGalectin Therapeutics’ belapectin shows reduction in new varicesFebruary 18, 2025 | markets.businessinsider.comSee More Headlines GALT Stock Analysis - Frequently Asked Questions How have GALT shares performed this year? Galectin Therapeutics' stock was trading at $1.29 at the beginning of 2025. Since then, GALT shares have increased by 7.4% and is now trading at $1.3860. View the best growth stocks for 2025 here. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) issued its earnings results on Monday, March, 31st. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.03. Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.06%) and FNY Investment Advisers LLC. Insiders that own company stock include James C Czirr, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Khurram Jamil, Harold H Shlevin and Jack W Callicutt. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings3/31/2025Today4/24/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GALT CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+697.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,070,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-163.15% Debt Debt-to-Equity RatioN/A Current Ratio1.13 Quick Ratio1.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.01) per share Price / Book-1.37Miscellaneous Outstanding Shares63,180,000Free Float31,318,000Market Cap$87.19 million OptionableOptionable Beta0.79 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:GALT) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.